Top

Published in:

01-03-2010

Lung cancer: From single-gene methylation to methylome profiling

Authors: Gerwin Heller, Christoph C. Zielinski, Sabine Zöchbauer-Müller

Published in: Cancer and Metastasis Reviews | Issue 1/2010

Abstract

DNA methylation as part of the epigenetic gene-silencing complex is a universal occurring change in lung cancer. Numerous studies investigated methylation of specific genes in primary tumors, in serum or plasma samples, and in specimens from the aerodigestive tract epithelium of lung cancer patients. In most studies, single genes or small numbers of genes were analyzed. Moreover, it has been observed that methylation of certain genes can already be detected in samples from the upper aerodigestive tract epithelium of cancer-free heavy smokers. These findings indicated that methylation of certain genes may be a useful biomarker for prognosis, disease recurrence, early detection, and lung cancer risk assessment. So far, several genes were identified which seem to be of worse prognostic relevance when they were found to be methylated. In addition, it has been shown that a panel of markers may be relevant to predict disease recurrence after surgery. In comparison to analysis of single or small numbers of genes, methods for genome-wide detection of methylation were developed recently. These approaches are focused on either pharmacological re-activation of methylated genes followed by expression microarray analysis or on microarray analysis of sodium bisulfite-treated or affinity-enriched methylated DNA sequences. With currently available methods for the simultaneous detection of methylation, up to 28,000 CpG islands can be analyzed. Overall, we are just at the beginning of translating these findings into the clinic and there is hope that future patients will benefit from these results.

Travis, W. D., Travis, L. B., & Devesa, S. S. (1995). Lung cancer. Cancer, 75, 191–202.PubMed

Shogren-Knaak, M., Ishii, H., Sun, J. M., Pazin, M. J., Davie, J. R., & Peterson, C. L. (2006). Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science, 311, 844–847.PubMed

Vettese-Dadey, M., Grant, P. A., Hebbes, T. R., Crane- Robinson, C., Allis, C. D., & Workman, J. L. (1996). Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. Embo Journal, 15, 2508–2518.PubMed

Esteller, M. (2008). Epigenetics in cancer. New England Journal of Medicine, 358, 1148–1159.PubMed

Espada, J., Ballestar, E., Fraga, M. F., Villar-Garea, A., Juarranz, A., Stockert, J. C., et al. (2004). Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. Journal of Biological Chemistry, 279, 37175–37184.PubMed

Ikegami, K., Ohgane, J., Tanaka, S., Yagi, S., & Shiota, K. (2009). Interplay between DNA methylation, histone modification and chromatin remodeling in stem cells and during development. International Journal of Developmental Biology, 53, 203–214.PubMed

Eden, S., Hashimshony, T., Keshet, I., Cedar, H., & Thorne, A. W. (1998). DNA methylation models histone acetylation. Nature, 394, 842.PubMed

Rhee, I., Jair, K. W., Yen, R. W., Lengauer, C., Herman, J. G., Kinzler, K. W., et al. (2000). CpG methylation is maintained in human cancer cells lacking DNMT1. Nature, 404, 1003–1007.PubMed

Gowher, H., & Jeltsch, A. (2001). Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from mouse: the enzyme modifies DNA in a non-processive manner and also methylates non-CpG [correction of non-CpA] sites. Journal of Molecular Biology, 309, 1201–1208.PubMed

10.

Okano, M., Xie, S., & Li, E. (1998). Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nature Genetics, 19, 219–220.PubMed

11.

Matsuo, K., Clay, O., Takahashi, T., Silke, J., & Schaffner, W. (1993). Evidence for erosion of mouse CpG islands during mammalian evolution. Somatic Cell and Molecular Genetics, 19, 543–555.PubMed

12.

Wang, Y., & Leung, F. C. (2004). An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics, 20, 1170–1177.PubMed

13.

Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409, 860–921.PubMed

14.

Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., et al. (2001). The sequence of the human genome. Science, 291, 1304–1351.PubMed

15.

Bird, A. P. (1986). CpG-rich islands and the function of DNA methylation. Nature, 321, 209–213.PubMed

16.

Gardiner-Garden, M., & Frommer, M. (1987). CpG islands in vertebrate genomes. Journal of Molecular Biology, 196, 261–282.PubMed

17.

Razin, A., & Cedar, H. (1994). DNA methylation and genomic imprinting. Cell, 77, 473–476.PubMed

18.

Jones, P. A., & Baylin, S. B. (2002). The fundamental role of epigenetic events in cancer. Nature Reviews. Genetics, 3, 415–428.PubMed

19.

Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics, 37, 391–400.PubMed

20.

Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., & Baylin, S. B. (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics, 21, 103–107.PubMed

21.

Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature Reviews. Cancer, 6, 857–866.PubMed

22.

He, L., & Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews. Genetics, 5, 522–531.PubMed

23.

Eulalio, A., Huntzinger, E., & Izaurralde, E. (2008). Getting to the root of miRNA-mediated gene silencing. Cell, 132, 9–14.PubMed

24.

Bueno, M. J., Perez de Castro, I., Gomez de Cedron, M., Santos, J., Calin, G. A., Cigudosa, J. C., et al. (2008). Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell, 13, 496–506.PubMed

25.

Brueckner, B., Stresemann, C., Kuner, R., Mund, C., Musch, T., Meister, M., et al. (2007). The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Research, 67, 1419–1423.PubMed

26.

Fazi, F., Racanicchi, S., Zardo, G., Starnes, L. M., Mancini, M., Travaglini, L., et al. (2007). Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell, 12, 457–466.PubMed

27.

Lujambio, A., Ropero, S., Ballestar, E., Fraga, M. F., Cerrato, C., Setien, F., et al. (2007). Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Research, 67, 1424–1429.PubMed

28.

Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Korner, H., et al. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle, 7, 2591–2600.PubMed

29.

Corney, D. C., Flesken-Nikitin, A., Godwin, A. K., Wang, W., & Nikitin, A. Y. (2007). MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Research, 67, 8433–8438.PubMed

30.

Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 104, 15805–15810.PubMed

31.

Shames, D. S., Minna, J. D., & Gazdar, A. F. (2007). Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Letters, 251, 187–198.PubMed

32.

Herman, J. G., & Baylin, S. B. (2001). Methylation-specific PCR. Current Protocols in Human Genetics, Chapter 10, Unit 10 16.

33.

Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., & Baylin, S. B. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America, 93, 9821–9826.PubMed

34.

Fraga, M. F., & Esteller, M (2002). DNA methylation: a profile of methods and applications. Biotechniques, 33, 632, 634, 636-649.

35.

Campan, M., Weisenberger, D. J., Trinh, B., & Laird, P. W. (2009). MethyLight. Methods in Molecular Biology, 507, 325–337.PubMed

36.

Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., & Pfeifer, G. P. (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nature Genetics, 25, 315–319.PubMed

37.

Esteller, M., Corn, P. G., Baylin, S. B., & Herman, J. G. (2001). A gene hypermethylation profile of human cancer. Cancer Research, 61, 3225–3229.PubMed

38.

Zöchbauer-Müller, S., Fong, K. M., Virmani, A. K., Geradts, J., Gazdar, A. F., & Minna, J. D. (2001). Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Research, 61, 249–255.PubMed

39.

Virmani, A. K., Rathi, A., Sathyanarayana, U. G., Padar, A., Huang, C. X., Cunnigham, H. T., et al. (2001). Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clinical Cancer Research, 7, 1998–2004.PubMed

40.

Virmani, A. K., Rathi, A., Zöchbauer-Müller, S., Sacchi, N., Fukuyama, Y., Bryant, D., et al. (2000). Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. Journal of the National Cancer Institute, 92, 1303–1307.PubMed

41.

Toyooka, K. O., Toyooka, S., Virmani, A. K., Sathyanarayana, U. G., Euhus, D. M., Gilcrease, M., et al. (2001). Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Research, 61, 4556–4560.PubMed

42.

Toyooka, S., Toyooka, K. O., Miyajima, K., Reddy, J. L., Toyota, M., Sathyanarayana, U. G., et al. (2003). Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clinical Cancer Research, 9, 3034–3041.PubMed

43.

Burbee, D. G., Forgacs, E., Zöchbauer-Müller, S., Shivakumar, L., Fong, K. M., Gao, B., et al. (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. Journal of the National Cancer Institute, 93, 691–699.PubMed

44.

Virmani, A., Rathi, A., Sugio, K., Sathyanarayana, U. G., Toyooka, S., Kischel, F. C., et al. (2003). Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. International Journal of Cancer, 106, 198–204.

45.

Zöchbauer-Müller, S., Fong, K. M., Maitra, A., Lam, S., Geradts, J., Ashfaq, R., et al. (2001). 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Research, 61, 3581–3585.PubMed

46.

Zöchbauer-Müller, S., Fong, K. M., Geradts, J., Xu, X., Seidl, S., End-Pfutzenreuter, A., et al. (2005). Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene, 24, 6249–6255.PubMed

47.

Heller, G., Fong, K. M., Girard, L., Seidl, S., End-Pfützenreuter, A., Lang, G., et al. (2006). Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene, 25, 959–968.PubMed

48.

Kikuchi, S., Yamada, D., Fukami, T., Masuda, M., Sakurai-Yageta, M., Williams, Y. N., et al. (2005). Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clinical Cancer Research, 11, 2954–2961.PubMed

49.

Kikuchi, S., Yamada, D., Fukami, T., Maruyama, T., Ito, A., Asamura, H., et al. (2006). Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer, 106, 1751–1758.PubMed

50.

Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S. B., & Herman, J. G. (1999). Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Research, 59, 67–70.PubMed

51.

Usadel, H., Brabender, J., Danenberg, K. D., Jeronimo, C., Harden, S., Engles, J., et al. (2002). Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Research, 62, 371–375.PubMed

52.

Hsu, H. S., Chen, T. P., Hung, C. H., Wen, C. K., Lin, R. K., Lee, H. C., et al. (2007). Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer, 110, 2019–2026.PubMed

53.

Fujiwara, K., Fujimoto, N., Tabata, M., Nishii, K., Matsuo, K., Hotta, K., et al. (2005). Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clinical Cancer Research, 11, 1219–1225.PubMed

54.

Wang, Y., Yu, Z., Wang, T., Zhang, J., Hong, L., & Chen, L. (2007). Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer, 56, 289–294.PubMed

55.

Belinsky, S. A., Klinge, D. M., Dekker, J. D., Smith, M. W., Bocklage, T. J., Gilliland, F. D., et al. (2005). Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clinical Cancer Research, 11, 6505–6511.PubMed

56.

Anglim, P. P., Alonzo, T. A., & Laird-Offringa, I. A. (2008). DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer, 7, 81.PubMed

57.

Wang, Y. C., Lu, Y. P., Tseng, R. C., Lin, R. K., Chang, J. W., Chen, J. T., et al. (2003). Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. Journal of Clinical Investigation, 111, 887–895.PubMed

58.

Belinsky, S. A., Liechty, K. C., Gentry, F. D., Wolf, H. J., Rogers, J., Vu, K., et al. (2006). Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Research, 66, 3338–3344.PubMed

59.

Belinsky, S. A., Grimes, M. J., Casas, E., Stidley, C. A., Franklin, W. A., Bocklage, T. J., et al. (2007). Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. British Journal of Cancer, 96, 1278–1283.PubMed

60.

Machida, E. O., Brock, M. V., Hooker, C. M., Nakayama, J., Ishida, A., Amano, J., et al. (2006). Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Research, 66, 6210–6218.PubMed

61.

Shivapurkar, N., Stastny, V., Suzuki, M., Wistuba, I. I., Li, L., Zheng, Y., et al. (2007). Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Letter, 247, 56–71.

62.

Schmiemann, V., Bocking, A., Kazimirek, M., Onofre, A. S., Gabbert, H. E., Kappes, R., et al. (2005). Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clinical Cancer Research, 11, 7728–7734.PubMed

63.

Grote, H. J., Schmiemann, V., Geddert, H., Rohr, U. P., Kappes, R., Gabbert, H. E., et al. (2005). Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer. International Journal of Cancer, 116, 720–725.

64.

Grote, H. J., Schmiemann, V., Kiel, S., Bocking, A., Kappes, R., Gabbert, H. E., et al. (2004). Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. International Journal of Cancer, 110, 751–755.

65.

Kim, H., Kwon, Y. M., Kim, J. S., Lee, H., Park, J. H., Shim, Y. M., et al. (2004). Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. Journal of Clinical Oncology, 22, 2363–2370.PubMed

66.

Chan, E. C., Lam, S. Y., Tsang, K. W., Lam, B., Ho, J. C., Fu, K. H., et al. (2002). Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clinical Cancer Research, 8, 3741–3746.PubMed

67.

Han, W., Wang, T., Reilly, A. A., Keller, S. M., & Spivack, S. D. (2009). Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respiratory Research, 10, 86.PubMed

68.

Toyooka, S., Toyooka, K. O., Maruyama, R., Virmani, A. K., Girard, L., Miyajima, K., et al. (2001). DNA methylation profiles of lung tumors. Mol Cancer Therapeutics, 1, 61–67.

69.

Gu, J., Berman, D., Lu, C., Wistuba, I. I., Roth, J. A., Frazier, M., et al. (2006). Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clinical Cancer Research, 12, 7329–7338.PubMed

70.

Ehrich, M., Field, J. K., Liloglou, T., Xinarianos, G., Oeth, P., Nelson, M. R., et al. (2006). Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Research, 66, 10911–10918.PubMed

71.

Toyooka, S., Tokumo, M., Shigematsu, H., Matsuo, K., Asano, H., Tomii, K., et al. (2006). Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Research, 66, 1371–1375.PubMed

72.

Tang, X., Khuri, F. R., Lee, J. J., Kemp, B. L., Liu, D., Hong, W. K., et al. (2000). Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. Journal of the National Cancer Institute, 92, 1511–1516.PubMed

73.

Lu, C., Soria, J. C., Tang, X., Xu, X. C., Wang, L., Mao, L., et al. (2004). Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. Journal of Clinical Oncology, 22, 4575–4583.PubMed

74.

Kim, D. H., Kim, J. S., Ji, Y. I., Shim, Y. M., Kim, H., Han, J., et al. (2003). Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Research, 63, 3743–3746.PubMed

75.

Tomizawa, Y., Kohno, T., Kondo, H., Otsuka, A., Nishioka, M., Niki, T., et al. (2002). Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clinical Cancer Research, 8, 2362–2368.PubMed

76.

Toyooka, S., Suzuki, M., Maruyama, R., Toyooka, K. O., Tsukuda, K., Fukuyama, Y., et al. (2004). The relationship between aberrant methylation and survival in non-small-cell lung cancers. British Journal of Cancer, 91, 771–774.PubMed

77.

Yanagawa, N., Tamura, G., Oizumi, H., Kanauchi, N., Endoh, M., Sadahiro, M., et al. (2007). Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer, 58, 131–138.PubMed

78.

Seng, T. J., Currey, N., Cooper, W. A., Lee, C. S., Chan, C., Horvath, L., et al. (2008). DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. British Journal of Cancer, 99, 375–382.PubMed

79.

Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., et al. (2008). DNA methylation markers and early recurrence in stage I lung cancer. New England Journal of Medicine, 358, 1118–1128.PubMed

80.

Parkin, D. M., Pisani, P., Lopez, A. D., & Masuyer, E. (1994). At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. International Journal of Cancer, 59, 494–504.

81.

Sun, S., Schiller, J. H., & Gazdar, A. F. (2007). Lung cancer in never smokers—a different disease. Nature Reviews Cancer, 7, 778–790.PubMed

82.

Toyooka, S., Maruyama, R., Toyooka, K. O., McLerran, D., Feng, Z., Fukuyama, Y., et al. (2003). Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. International Journal of Cancer, 103, 153–160.

83.

Belinsky, S. A., Palmisano, W. A., Gilliland, F. D., Crooks, L. A., Divine, K. K., Winters, S. A., et al. (2002). Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Research, 62, 2370–2377.PubMed

84.

Damiani, L. A., Yingling, C. M., Leng, S., Romo, P. E., Nakamura, J., & Belinsky, S. A. (2008). Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Research, 68, 9005–9014.PubMed

85.

Shen, H., Spitz, M. R., Qiao, Y., Guo, Z., Wang, L. E., Bosken, C. H., et al. (2003). Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. International Journal of Cancer, 107, 84–88.

86.

Leng, S., Stidley, C. A., Willink, R., Bernauer, A., Do, K., Picchi, M. A., et al. (2008). Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation. Cancer Research, 68, 3049–3056.PubMed

87.

Kersting, M., Friedl, C., Kraus, A., Behn, M., Pankow, W., & Schuermann, M. (2000). Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. Journal of Clinical Oncology, 18, 3221–3229.PubMed

88.

Honorio, S., Agathanggelou, A., Schuermann, M., Pankow, W., Viacava, P., Maher, E. R., et al. (2003). Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene, 22, 147–150.PubMed

89.

Lamy, A., Sesboue, R., Bourguignon, J., Dautreaux, B., Metayer, J., Frebourg, T., et al. (2002). Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. International Journal of Cancer, 100, 189–193.

90.

Soria, J. C., Rodriguez, M., Liu, D. D., Lee, J. J., Hong, W. K., & Mao, L. (2002). Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Research, 62, 351–355.PubMed

91.

Zöchbauer-Müller, S., Lam, S., Toyooka, S., Virmani, A. K., Toyooka, K. O., Seidl, S., et al. (2003). Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. International Journal of Cancer, 107, 612–616.

92.

Bhutani, M., Pathak, A. K., Fan, Y. H., Liu, D. D., Lee, J. J., Tang, H., et al. (2008). Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prevention Researcg (Philadelphia, PA), 1, 39–44.

93.

Licchesi, J. D., Westra, W. H., Hooker, C. M., & Herman, J. G. (2008). Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clinical Cancer Research, 14, 2570–2578.PubMed

94.

Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., et al. (2000). Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Research, 60, 5954–5958.PubMed

95.

http://www.fda.gov/ Dacogen (decitabine), NDA# N21790.

96.

Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L. S., Lee, S. L., et al. (2005). Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical Cancer Research, 11, 3604–3608.PubMed

97.

Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., et al. (2007). Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clinical Cancer Research, 13, 2318–2322.PubMed

98.

Piekarz R, Wright J, Frye R, Allen SL, Craig M, Geskin L, et al. (2008). Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). ASH Annual Meeting Abstracts, 112.

99.

Juergens, R., Vendetti, F., Coleman, B., Sebree, R., Belinsky, S., Rudek, M., et al. (2009). A phase II-trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC): an interim analysis. Abstract# A6.6, 13th World Conference on Lung Cancer (WCLC).

100.

Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., et al. (2000). Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics, 24, 132–138.PubMed

101.

Dai, Z., Lakshmanan, R. R., Zhu, W. G., Smiraglia, D. J., Rush, L. J., Fruhwald, M. C., et al. (2001). Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia, 3, 314–323.PubMed

102.

Brena, R. M., Morrison, C., Liyanarachchi, S., Jarjoura, D., Davuluri, R. V., Otterson, G. A., et al. (2007). Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med, 4, e108.PubMed

103.

Weber, M., Davies, J. J., Wittig, D., Oakeley, E. J., Haase, M., Lam, W. L., et al. (2005). Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics, 37, 853–862.PubMed

104.

Dammann, R., Yang, G., & Pfeifer, G. P. (2001). Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Research, 61, 3105–3109.PubMed

105.

Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M. P., et al. (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics, 31, 141–149.PubMed

106.

Shames, D. S., Girard, L., Gao, B., Sato, M., Lewis, C. M., Shivapurkar, N., et al. (2006). A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Medicine, 3, e486.PubMed

107.

Zhong, S., Fields, C. R., Su, N., Pan, Y. X., & Robertson, K. D. (2007). Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene, 26, 2621–2634.PubMed

108.

Bestor, T. H. (2003). Unanswered questions about the role of promoter methylation in carcinogenesis. Annals of the New York Academy of Sciences, 983, 22–27.PubMed

109.

Sato, N., Fukushima, N., Maitra, A., Matsubayashi, H., Yeo, C. J., Cameron, J. L., et al. (2003). Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Research, 63, 3735–3742.PubMed

110.

Bibikova, M., Lin, Z., Zhou, L., Chudin, E., Garcia, E. W., Wu, B., et al. (2006). High-throughput DNA methylation profiling using universal bead arrays. Genome Research, 16, 383–393.PubMed

111.

Christensen, B. C., Marsit, C. J., Houseman, E. A., Godleski, J. J., Longacker, J. L., Zheng, S., et al. (2009). Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Research, 69, 6315–6321.PubMed

112.

Mockler, T. C., Chan, S., Sundaresan, A., Chen, H., Jacobsen, S. E., & Ecker, J. R. (2005). Applications of DNA tiling arrays for whole-genome analysis. Genomics, 85, 1–15.PubMed

113.

Rauch, T. A., Zhong, X., Wu, X., Wang, M., Kernstine, K. H., Wang, Z., et al. (2008). High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 105, 252–257.PubMed

114.

Tessema, M., Willink, R., Do, K., Yu, Y. Y., Yu, W., Machida, E. O., et al. (2008). Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Research, 68, 1707–1714.PubMed

115.

Zhang, Z., Tan, S., & Zhang, L. (2006). Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer. Clinical Lung Cancer, 8, 62–65.PubMed

116.

Nakata, S., Sugio, K., Uramoto, H., Oyama, T., Hanagiri, T., Morita, M., et al. (2006). The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer, 106, 2190–2199.PubMed

117.

Maruyama, R., Sugio, K., Yoshino, I., Maehara, Y., & Gazdar, A. F. (2004). Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer, 100, 1472–1477.PubMed

118.

Brabender, J., Usadel, H., Danenberg, K. D., Metzger, R., Schneider, P. M., Lord, R. V., et al. (2001). Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene, 20, 3528–3532.PubMed

119.

Agathanggelou, A., Honorio, S., Macartney, D. P., Martinez, A., Dallol, A., Rader, J., et al. (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509–1518.PubMed

120.

Dammann, R., Takahashi, T., & Pfeifer, G. P. (2001). The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene, 20, 3563–3567.PubMed

121.

Kashiwabara, K., Oyama, T., Sano, T., Fukuda, T., & Nakajima, T. (1998). Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. International Journal of Cancer, 79, 215–220.

122.

Kuramochi, M., Fukuhara, H., Nobukuni, T., Kanbe, T., Maruyama, T., Ghosh, H. P., et al. (2001). TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nature Genetics, 27, 427–430.PubMed

123.

Brabender, J., Usadel, H., Metzger, R., Schneider, P. M., Park, J., Salonga, D., et al. (2003). Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clinical Cancer Research, 9, 223–227.PubMed

Title: Lung cancer: From single-gene methylation to methylome profiling
Authors: Gerwin Heller
Christoph C. Zielinski
Sabine Zöchbauer-Müller
Publication date: 01-03-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9203-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Modeling prostate cancer: a perspective on transgenic mouse models

Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer

Biography—Adi Gazdar

EGFR mutations and the terminal respiratory unit

Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives

Cetuximab in combination therapy: from bench to clinic

Keynote webinar | Spotlight on antibody–drug conjugates in cancer